Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by AWM Investment Company Inc.

AWM Investment Company Inc. grew its stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 22.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 687,831 shares of the company's stock after acquiring an additional 128,100 shares during the quarter. AWM Investment Company Inc. owned about 2.55% of Alto Neuroscience worth $2,910,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ANRO. JPMorgan Chase & Co. raised its holdings in shares of Alto Neuroscience by 543.4% during the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company's stock valued at $278,000 after purchasing an additional 20,536 shares during the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of Alto Neuroscience during the 4th quarter valued at $1,575,000. Rhumbline Advisers lifted its holdings in shares of Alto Neuroscience by 24.4% during the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock valued at $108,000 after buying an additional 5,008 shares during the period. Barclays PLC boosted its stake in shares of Alto Neuroscience by 34.5% in the 4th quarter. Barclays PLC now owns 39,807 shares of the company's stock worth $168,000 after buying an additional 10,208 shares during the last quarter. Finally, Stifel Financial Corp bought a new stake in shares of Alto Neuroscience in the fourth quarter worth $544,000.

Alto Neuroscience Stock Performance

Alto Neuroscience stock traded up $0.12 during trading on Monday, reaching $3.05. The company had a trading volume of 276,114 shares, compared to its average volume of 386,348. The firm has a market capitalization of $82.68 million, a price-to-earnings ratio of -1.31 and a beta of 1.87. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The firm's 50-day simple moving average is $2.35 and its 200 day simple moving average is $3.39. Alto Neuroscience, Inc. has a 52 week low of $1.60 and a 52 week high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. Sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ANRO. William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. HC Wainwright initiated coverage on Alto Neuroscience in a research note on Monday, April 7th. They set a "buy" rating and a $10.00 price target for the company. Finally, Wedbush reiterated a "neutral" rating and issued a $4.00 price objective on shares of Alto Neuroscience in a research note on Thursday, May 15th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $15.40.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.